AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03666299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
Study NCT03666299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
Study NCT01508923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study NCT01508923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study NCT01508923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study NCT01508923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study NCT02996461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
Study NCT00993629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnenolone
Description: Administered adjunctively to treatment as usual
Study NCT00993629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: adjunctive placebo
Study NCT00003276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT01812044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: subtenons control - 0.5 cc of Normal Saline
Study NCT02742103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL_112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
Study NCT02742103 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study NCT01297218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Description: DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
Study NCT03447327 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: single burr hole
Description: patients with CSDH operated by single burr hole craniostomy under local anaesthesia
Study NCT01818336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin skin test kit
Description: Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
Study NCT01709318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAC)
Description: Daily release of 500, 700, or 900 μg.
Study NCT04435912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 200mg IV
Description: single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
Study NCT01709318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG)
Description: Daily release of 75, 100, 120 or 125 μg
Study NCT01709318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel (ENG)
Description: Daily release of 75, 100, 120 or 125 μg
Study NCT01709318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl estradiol (EE)
Description: Daily release of 15 μg
Study NCT01709318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Description: Daily release of 300 μg
Study NCT00320281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
Study NCT00320281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
Study NCT02755948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37
Description: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
Study NCT02755948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/California/04/2009-likw (H1N1)
Description: Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
Study NCT02755948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/Belgium/4217/2015 (H3N2)
Description: Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
Study NCT00689273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Description: 125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
Study NCT00689273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
Study NCT01125917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
Study NCT01125917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
Study NCT01125917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
Study NCT03841903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spinal cord MRI
Description: high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
Study NCT03574194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methionine-restricted diet
Description: The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
Study NCT01922973 — intervention group
Intervention type: OTHER
Intervention: Fasting
Description: normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
Study NCT04064931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of niacin and other vitamins in plasma
Description: Detection of niacin and other vitamins in plasma
Study NCT02107768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate.
Study NCT03979339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
Study NCT03101215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phosphorus
Description: adding of phosphorus to high carbohydrate meal
Study NCT03101215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phosphorus
Description: adding of phosphorus to high carbohydrate meal
Study NCT04306224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-002
Description: IMC-002 blocks the interaction between CD47 and SIRPα.
Study NCT05297994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [Inactivated split influenza vaccine]
Description: solution for intramuscular injection, 0.5 ml
Study NCT05297994 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza split vaccine
Description: solution for intramuscular injection, 0.5 ml
Study NCT01253616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation (VNS)
Description: Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
Study NCT01156324 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Online Stress Management Group (Upliv)
Description: Personalized online stress management program
Study NCT01156324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group receiving routine care along with $50 gift certificate at end of cycle
Study NCT04747938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy accumulator
Description: All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
Study NCT04747938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
Study NCT01003431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: \[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
Study NCT01003431 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)
Description: Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
Study NCT01003431 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)
Description: Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
Study NCT02120339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT03269279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Medication used in conjunction with misoprostol for abortion
Study NCT03269279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Medication used in conjunction with mifepristone for abortion
Study NCT02993601 — intervention group
Intervention type: DEVICE
Intervention: Heartfelt-1
Description: The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
Study NCT02993601 — intervention group
Intervention type: DEVICE
Intervention: Weighing scales
Description: The patient will be asked to stand on standard medical weighing scales, to measure their weight.
Study NCT02993601 — intervention group
Intervention type: OTHER
Intervention: Medical grading of oedema
Description: A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
Study NCT02993601 — intervention group
Intervention type: OTHER
Intervention: Baseline assessements
Description: At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
Study NCT02993601 — intervention group
Intervention type: DEVICE
Intervention: Water displacement method
Description: This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
Study NCT02993601 — intervention group
Intervention type: DEVICE
Intervention: Callipers measurements
Description: This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
Study NCT02993601 — intervention group
Intervention type: DEVICE
Intervention: Measuring tape
Description: The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
Study NCT02305940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
Study NCT02305940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
Study NCT02690246 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: a questionnaire based study
Study NCT04521010 — intervention group
Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
Study NCT00646958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 450mg PO QD
Study NCT00646958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radezolid
Description: 450mg PO BID
Study NCT00646958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600mg PO BID
Study NCT05134376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music
Description: Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
Study NCT00533949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
Study NCT00533949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22.
Study NCT00533949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22.
Study NCT00533949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.
Study NCT00533949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22.
Study NCT00533949 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 60 Gy RT
Description: Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
Study NCT00533949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60 Gy RT
Description: Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
Study NCT00533949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 74 Gy RT
Description: Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
Study NCT00228878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effects of Pulsatile IV insulin on Diabetic Quality of Life
Description: Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
Study NCT02915718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protein A immunoadsorption
Description: protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
Study NCT05078632 — intervention group
Intervention type: OTHER
Intervention: Montreal-Toulouse Test adapted in eye tracking
Description: participant pass an eye tracking test to evaluate comprehension
Study NCT03830333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
Study NCT03830333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
Study NCT01429896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
Study NCT01624545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cranial CT scan
Description: Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
Study NCT02912884 — intervention group
Intervention type: DRUG
Intervention: No cytoreductive vs cytoreductive drugs
Description: No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).